Inflammatory biomarkers have a prognostic role in patients with metastatic castration‐resistant prostate cancer treated with Lutetium‐177–PSMA‐617
Margo B. Gerke(Emory University), Mehmet Asım Bilen(Emory Healthcare), Shahid Ahmed(Emory University), Saima Muzahir(Emory University), Akshay Bedmutha(Emory University), David M. Schuster(Emory University), Jacob E. Berchuck(Dana-Farber Cancer Institute), Angelo Marra(Emory University), Bassel Nazha(Emory University), Jordan Ciuro(Emory University), Sarah Caulfield(Emory University), J L Brown(Emory University), Ravi B. Parikh(Emory University), Caitlin Hartman(Emory University), Bradley Curtis Carthon(Emory University), O. Kucuk(Emory University), Yuan Liu(Emory University), Greta Russler McClintock(Emory University)
Cited by 2
Related Papers
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
|The Lancet Oncology|2017|1.1k
Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management
|Cancers|2023|640
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium
|Annals of Oncology|2021|328
Gallbladder Cancer in the 21st Century
|Journal of Oncology|2015|301